Corvus Pharmaceuticals (CRVS) Projected to Post Quarterly Earnings on Thursday

Corvus Pharmaceuticals (CRVS) is expected to report its Q4 2025 earnings before the market opens on Thursday, March 12th, with analysts projecting a loss of ($0.14) per share. Several analysts have recently increased their price targets for CRVS, with the average target now at $31.80 and a “Moderate Buy” consensus rating. The stock’s performance shows recent trading at $15.80, a wide 52-week range, and significant institutional interest.

此页面可能包含第三方内容,仅供参考(非陈述/保证),不应被视为 Gate 认可其观点表述,也不得被视为财务或专业建议。详见声明
  • 赞赏
  • 评论
  • 转发
  • 分享
评论
请输入评论内容
请输入评论内容
暂无评论